GlassScriptPhysician profile
Gabor Racz
NPI 1871595124
$2,988,062.78
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $505K · 2020: $416K · 2021: $430K · 2022: $445K · 2023: $687K · 2024: $505K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Royalty Or License: $786K · Acquisitions: $240K · Consulting Fee: $166K · Food and Beverage: $515.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Royalty Or License | $785,537.08 |
| Acquisitions | $240,000.00 |
| Consulting Fee | $165,786.07 |
| Food and Beverage | $515.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Epimed International, INC | $2,746,944.28 | 2019-2024 | Catheters and Needles, Needles and Catheters |
| Curonix LLC | $240,097.95 | 2023-2024 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Stimwave Technologies Incorporated | $333.91 | 2019-2021 | |
| Biotronik Nro, INC. | $148.12 | 2024 | Prospera |
| Medtronic, INC. | $146.27 | 2021 | |
| Boston Scientific Corporation | $139.01 | 2023-2024 | Wavewriter Alpha Prime 16 |
| Nalu Medical, INC. | $80.22 | 2024 | Nalu Neurostimulation System |
| Spr Therapeutics, INC | $78.00 | 2022 | |
| Abbvie INC. | $49.99 | 2024 | |
| Nevro Corp. | $45.03 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gabor Racz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.